CA2598786C - Composition et procede d'augmentation de l'anabolisme des cellules musculaires - Google Patents
Composition et procede d'augmentation de l'anabolisme des cellules musculaires Download PDFInfo
- Publication number
- CA2598786C CA2598786C CA2598786A CA2598786A CA2598786C CA 2598786 C CA2598786 C CA 2598786C CA 2598786 A CA2598786 A CA 2598786A CA 2598786 A CA2598786 A CA 2598786A CA 2598786 C CA2598786 C CA 2598786C
- Authority
- CA
- Canada
- Prior art keywords
- composition
- muscle
- hydroxy
- chain amino
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 230000001965 increasing effect Effects 0.000 title abstract description 33
- 238000000034 method Methods 0.000 title abstract description 14
- 230000001195 anabolic effect Effects 0.000 title description 5
- 210000000663 muscle cell Anatomy 0.000 title description 4
- XXRCUYVCPSWGCC-UHFFFAOYSA-N Ethyl pyruvate Chemical compound CCOC(=O)C(C)=O XXRCUYVCPSWGCC-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229940117360 ethyl pyruvate Drugs 0.000 claims abstract description 26
- 210000003205 muscle Anatomy 0.000 claims abstract description 23
- 239000002207 metabolite Substances 0.000 claims abstract description 14
- 238000004090 dissolution Methods 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 4
- 230000007246 mechanism Effects 0.000 claims description 4
- 239000006186 oral dosage form Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 2
- NGEWQZIDQIYUNV-UHFFFAOYSA-N 2-hydroxy-3-methylbutyric acid Chemical compound CC(C)C(O)C(O)=O NGEWQZIDQIYUNV-UHFFFAOYSA-N 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 abstract description 28
- 150000005693 branched-chain amino acids Chemical class 0.000 abstract description 23
- 230000001413 cellular effect Effects 0.000 abstract description 12
- 239000004615 ingredient Substances 0.000 abstract description 8
- 210000004369 blood Anatomy 0.000 abstract description 5
- 239000008280 blood Substances 0.000 abstract description 5
- LVRFTAZAXQPQHI-UHFFFAOYSA-N 2-hydroxy-4-methylvaleric acid Chemical compound CC(C)CC(O)C(O)=O LVRFTAZAXQPQHI-UHFFFAOYSA-N 0.000 description 48
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 24
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 24
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 23
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 229940076788 pyruvate Drugs 0.000 description 17
- NGEWQZIDQIYUNV-BYPYZUCNSA-N (S)-2-hydroxy-3-methylbutyric acid Chemical compound CC(C)[C@H](O)C(O)=O NGEWQZIDQIYUNV-BYPYZUCNSA-N 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 210000003470 mitochondria Anatomy 0.000 description 12
- 208000010444 Acidosis Diseases 0.000 description 10
- 230000015556 catabolic process Effects 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 235000016709 nutrition Nutrition 0.000 description 9
- 230000007950 acidosis Effects 0.000 description 8
- 208000026545 acidosis disease Diseases 0.000 description 8
- 239000002775 capsule Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000001243 protein synthesis Methods 0.000 description 7
- 230000014616 translation Effects 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 210000002027 skeletal muscle Anatomy 0.000 description 6
- 239000007894 caplet Substances 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000000446 fuel Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000003387 muscular Effects 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000000153 supplemental effect Effects 0.000 description 4
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 4
- OCUSNPIJIZCRSZ-ZTZWCFDHSA-N (2s)-2-amino-3-methylbutanoic acid;(2s)-2-amino-4-methylpentanoic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound CC(C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O OCUSNPIJIZCRSZ-ZTZWCFDHSA-N 0.000 description 3
- BKAJNAXTPSGJCU-UHFFFAOYSA-N 4-methyl-2-oxopentanoic acid Chemical compound CC(C)CC(=O)C(O)=O BKAJNAXTPSGJCU-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000000562 Monocarboxylic Acid Transporters Human genes 0.000 description 3
- 108010041817 Monocarboxylic Acid Transporters Proteins 0.000 description 3
- 102000008934 Muscle Proteins Human genes 0.000 description 3
- 108010074084 Muscle Proteins Proteins 0.000 description 3
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000003139 buffering effect Effects 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000002414 glycolytic effect Effects 0.000 description 3
- -1 hydrogen ions Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000007363 ring formation reaction Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 229940123457 Free radical scavenger Drugs 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 206010027417 Metabolic acidosis Diseases 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 230000003160 anti-catabolic effect Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000007882 dietary composition Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000020930 dietary requirements Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 230000034659 glycolysis Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 150000002614 leucines Chemical class 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 208000015001 muscle soreness Diseases 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LVRFTAZAXQPQHI-RXMQYKEDSA-N (R)-2-hydroxy-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](O)C(O)=O LVRFTAZAXQPQHI-RXMQYKEDSA-N 0.000 description 1
- YRWAMSXHYBBHFL-UHFFFAOYSA-N 4-hydroxy-4-methyl-2-oxoglutaric acid Chemical compound OC(=O)C(O)(C)CC(=O)C(O)=O YRWAMSXHYBBHFL-UHFFFAOYSA-N 0.000 description 1
- STRMKLRTINNHSQ-UHFFFAOYSA-N C(C(=O)C)(=O)O.C(C(=O)C)(=O)OCC Chemical compound C(C(=O)C)(=O)O.C(C(=O)C)(=O)OCC STRMKLRTINNHSQ-UHFFFAOYSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 206010007733 Catabolic state Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 101000937642 Homo sapiens Malonyl-CoA-acyl carrier protein transacylase, mitochondrial Proteins 0.000 description 1
- 101000590830 Homo sapiens Monocarboxylate transporter 1 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 102100027329 Malonyl-CoA-acyl carrier protein transacylase, mitochondrial Human genes 0.000 description 1
- 240000002129 Malva sylvestris Species 0.000 description 1
- 235000006770 Malva sylvestris Nutrition 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010071051 Soft tissue mass Diseases 0.000 description 1
- 229940100228 acetyl coenzyme a Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000020827 calorie restriction Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 231100000284 endotoxic Toxicity 0.000 description 1
- 230000002346 endotoxic effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 235000020650 eye health related herbal supplements Nutrition 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 210000004536 heart mitochondria Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000005026 intestinal epithelial barrier Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004844 protein turnover Effects 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000004096 skeletal muscle tissue growth Effects 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 210000003699 striated muscle Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Neurology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention porte sur une supplément nutritionnel contenant au moins une quantité thérapeutiquement efficace de pyruvate d'éthyle et une quantité thérapeutiquement efficace d'au moins un métabolite d'un acide aminé alpha-hydroxy ramifié. Les ingrédients du supplément nutritionnel agissent simultanément pour induire un état favorable sur la plan anabolique dans le muscle, pour maintenir un pH physiologique dans le sang et le muscle et pour augmenter la concentration cellulaire d'acides aminés ramifiés. Une composition et une méthode sont divulguées dans la présente invention.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2598786A CA2598786C (fr) | 2007-09-11 | 2007-09-11 | Composition et procede d'augmentation de l'anabolisme des cellules musculaires |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2598786A CA2598786C (fr) | 2007-09-11 | 2007-09-11 | Composition et procede d'augmentation de l'anabolisme des cellules musculaires |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2598786A1 CA2598786A1 (fr) | 2008-12-16 |
| CA2598786C true CA2598786C (fr) | 2012-01-03 |
Family
ID=40134902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2598786A Expired - Fee Related CA2598786C (fr) | 2007-09-11 | 2007-09-11 | Composition et procede d'augmentation de l'anabolisme des cellules musculaires |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2598786C (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021198788A1 (fr) * | 2020-03-30 | 2021-10-07 | Compagnie Gervais Danone | Compositions de lait fermenté destinées à être utilisées dans des procédés de supplémentation nutritionnelle |
-
2007
- 2007-09-11 CA CA2598786A patent/CA2598786C/fr not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2598786A1 (fr) | 2008-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10052298B2 (en) | Rapid-acting, blood-arginine-level-increasable oral preparation comprising citrulline and arginine | |
| US7790688B2 (en) | Compositions and methods for increasing muscle mass, strength, and functional performance in the elderly | |
| US6521591B1 (en) | Pharmaceutical composition for muscular anabolism | |
| US5863906A (en) | Composition based on amino acids intended for the treatment of sepsis or of an attack bringing about an inflammatory reaction, in animals and man | |
| ES2207287T3 (es) | Uso de carnitinas y resveratrol para producir una composicion para la prevencion o tratamiento terapeutico de trastornos cerebrales producidos por el envejecimiento y uso de farmacos neurotoxicos. | |
| JP2002542191A (ja) | グルタチオンの吸収を増しかつその効果を補強するのに有用な、カルニチンおよびグルタチオン含有組成物 | |
| US20100166796A1 (en) | Method of increasing cellular function and health of glutathione deficient animals | |
| US20090156647A1 (en) | Method for maintaining physiological pH levels during intensive physical exercise | |
| US20020002198A1 (en) | Chemical synergy to elevate growth hormone release in vertebrates | |
| CA2598786C (fr) | Composition et procede d'augmentation de l'anabolisme des cellules musculaires | |
| US7956090B2 (en) | Composition and method for increasing the anabolic state of muscle cells | |
| US20080242727A1 (en) | Dietary compositions containing alpha amino n-butyrate and methods of enhancing lean body mass | |
| AU2007358961A1 (en) | Composition and method for increasing the anabolic state of muscle cells | |
| CA2134380C (fr) | Composition a base d'acides amines servant au traitement de la septicemie ou d'une atteinte induisant une reaction inflammatoire | |
| US20090005320A1 (en) | Compositions comprising amino acid bicarbonate and methods of use thereof | |
| US20070072927A1 (en) | Nutritional supplement for increased energy and stamina | |
| WO2011160259A1 (fr) | Utilisation d'acide n-carbamoylglutamique, ses sels ou esters, dans la fabrication de produits de soin de santé pour la protection du foie ou la promotion du développement musculaire | |
| Nomura et al. | EFFECT OF DIETARY PROTEIN ON URINARY 5‐HYDROXYINDOLEACETIC ACID LEVELS 1 | |
| US20120316121A1 (en) | Materials and Methods for Modulating Arginine Metabolism | |
| US20110189312A1 (en) | Compositions and Methods for Supporting Heat Shock Protein Function | |
| CA2610820A1 (fr) | Supplement nutritionnel stabilisant les niveaux de ph physiologiques lors d'un exercice intensif | |
| WO2023166074A1 (fr) | Acides gras pour favoriser un régime cétogène | |
| CZ20004620A3 (cs) | Přípravek obsahující karnitin a glutathion, vhodný pro zvýšení absorpce glutathionu a zesílení jeho účinků | |
| WO2009073944A1 (fr) | Utilisation de pyridoxine alpha-hydroxyisocaproate pour réduire l'acidose métabolique et l'accumulation d'ammoniac | |
| WO2009043136A1 (fr) | Amélioration de l'état énergétique d'un individu par une augmentation de l'usage d'une source d'énergie endogène |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20220912 |